These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1130 related items for PubMed ID: 23974954

  • 41. Adalimumab induces deep remission in patients with Crohn's disease.
    Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J.
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
    [Abstract] [Full Text] [Related]

  • 42. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
    Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P.
    Inflamm Bowel Dis; 2009 Mar; 15(3):375-82. PubMed ID: 19009634
    [Abstract] [Full Text] [Related]

  • 43. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, Szymanska S, Woynarowski M, Ryzko J.
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [Abstract] [Full Text] [Related]

  • 44. Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease?
    Turner D, Levine A, Walters TD, Focht G, Otley A, López VN, Koletzko S, Baldassano R, Mack D, Hyams J, Griffiths AM.
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):254-260. PubMed ID: 27050050
    [Abstract] [Full Text] [Related]

  • 45. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection.
    Regueiro M, Kip KE, Schraut W, Baidoo L, Sepulveda AR, Pesci M, El-Hachem S, Harrison J, Binion D.
    Inflamm Bowel Dis; 2011 Jan; 17(1):118-26. PubMed ID: 20848538
    [Abstract] [Full Text] [Related]

  • 46. Intestinal wall thickness detected by multidetector spiral computed tomography enterography predicts the disease severity of Crohn's disease.
    Yang X, Yu L, Yu W, Tang M, He C, Li Z, Liu Z.
    Scand J Gastroenterol; 2014 Jul; 49(7):807-13. PubMed ID: 24730384
    [Abstract] [Full Text] [Related]

  • 47. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease.
    Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ.
    Am J Gastroenterol; 2009 Nov; 104(11):2768-73. PubMed ID: 19672253
    [Abstract] [Full Text] [Related]

  • 48. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
    Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG.
    Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
    [Abstract] [Full Text] [Related]

  • 49. C-reactive protein and monitoring the activity of Crohn's disease.
    Filik L, Dagli U, Ulker A.
    Adv Ther; 2006 Oct; 23(4):655-62. PubMed ID: 17050508
    [Abstract] [Full Text] [Related]

  • 50. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G.
    Lancet; 2017 Dec 23; 390(10114):2779-2789. PubMed ID: 29096949
    [Abstract] [Full Text] [Related]

  • 51. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ.
    Gastroenterology; 2011 Oct 23; 141(4):1194-201. PubMed ID: 21723220
    [Abstract] [Full Text] [Related]

  • 52. Slight increases in the disease activity index and platelet count imply the presence of active intestinal lesions in C-reactive protein-negative Crohn's disease patients.
    Nakarai A, Kato J, Hiraoka S, Inokuchi T, Takei D, Morito Y, Akita M, Takahashi S, Hori K, Harada K, Okada H, Yamamoto K.
    Intern Med; 2014 Oct 23; 53(17):1905-11. PubMed ID: 25175121
    [Abstract] [Full Text] [Related]

  • 53. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D, Semapimod-CD04/CD05 Investigators.
    Gut; 2010 Jun 23; 59(6):760-6. PubMed ID: 20551461
    [Abstract] [Full Text] [Related]

  • 54. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.
    Am J Gastroenterol; 2008 Jan 23; 103(1):162-9. PubMed ID: 17916108
    [Abstract] [Full Text] [Related]

  • 55. Infliximab prevents Crohn's disease recurrence after ileal resection.
    Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE.
    Gastroenterology; 2009 Feb 23; 136(2):441-50.e1; quiz 716. PubMed ID: 19109962
    [Abstract] [Full Text] [Related]

  • 56. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
    Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I.
    World J Gastroenterol; 2019 Apr 14; 25(14):1764-1774. PubMed ID: 31011260
    [Abstract] [Full Text] [Related]

  • 57. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.
    Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ.
    Inflamm Bowel Dis; 2020 Jan 06; 26(2):304-313. PubMed ID: 31644790
    [Abstract] [Full Text] [Related]

  • 58. [Mucosal healing in different intestinal segments in patients receiving infliximab treatment for small bowel Crohn's disease].
    Zhu ZH, Qiu C, Zhang M, Chen Z, Xiang C, Wang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan 20; 37(1):44-48. PubMed ID: 28109097
    [Abstract] [Full Text] [Related]

  • 59. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D, GETAID.
    Gastroenterology; 2018 Apr 20; 154(5):1343-1351.e1. PubMed ID: 29317275
    [Abstract] [Full Text] [Related]

  • 60. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study.
    Yamamoto T, Umegae S, Matsumoto K.
    Inflamm Bowel Dis; 2009 Oct 20; 15(10):1460-6. PubMed ID: 19266566
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.